Willow Park

Researchers are studying intravitreal EYE103 in people with neovascular age-related macular degeneration (NVAMD) or macular edema after branch retinal vein occlusion (BRVO). This phase 2 randomized, dose-masked trial includes four patient groups, with participants randomly assigned to receive either a low or high dose of EYE103. Some groups include treatment-naïve participants, while others involve incomplete responders, including a group receiving EYE103 combined with aflibercept, a standard anti-VEGF medication. Participants will receive three injections of EYE103 in the study eye, spaced four weeks apart. Those in the combination therapy group will receive an additional aflibercept injection on the first day. The study will be conducted in sequential cohorts, with each group receiving their assigned treatment dose. Participants will have safety and effectiveness assessments at each injection visit, with some returning two weeks post-injection for extra evaluations. During the study, participants will undergo vision tests using the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart and eye examinations such as slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT) to measure retinal thickness. The main outcome is the change in best-corrected visual acuity at week 12. The study concludes at the week 12 visit, which marks the end of participation for all enrolled individuals.

This research aims to assess the long-term safety and tolerability of JNJ-81201887, a medicine given by injection into the eye, in people with geographic atrophy secondary to age-related macular degeneration. The study includes participants who were previously treated in earlier clinical studies of this medicine. The main goal is to monitor any eye or systemic side effects and abnormal findings over up to five years. Participants who received low or high doses of JNJ-81201887 in earlier studies, as well as those initially given a sham procedure who may have later received the medicine, will join this extension study. No new treatments or injections will be given during this long-term study. It is designed as a randomized, triple-masked phase 2 trial to carefully observe participants over time. During the study, participants will have regular eye examinations, retinal imaging, and laboratory tests to check for any changes or adverse events related to the earlier treatment. Researchers will track ocular and systemic treatment-emergent adverse events for up to five years. Participants will be involved throughout this period with scheduled visits to monitor their condition and safety status consistently.

Researchers are evaluating the effectiveness of EYP-1901, a tyrosine kinase inhibitor, compared to Aflibercept in treating diabetic macular edema (DME). This phase 3, randomized, double-masked study aims to assess how well these treatments improve vision in participants with DME, a condition related to diabetic retinopathy that affects the central part of the retina. Participants will receive intravitreal injections of either EYP-1901 or Aflibercept. The study is designed with parallel groups and a quadruple masking approach, meaning neither participants nor researchers will know which treatment is given. The treatments will be administered according to the study schedule, with monitoring throughout the trial period. During the study, participants will undergo assessments including measuring best corrected visual acuity (BCVA) at 52 and 56 weeks to evaluate changes in vision. The study will also track the rate of injections needed by week 56. Safety and treatment effects will be monitored throughout the trial, which is expected to continue until October 2028.

Researchers are evaluating the safety and effectiveness of a single intravitreal injection of 4D-150 in adults aged 50 and older with macular neovascularization caused by neovascular age-related macular degeneration (nAMD). This Phase 3 trial compares 4D-150 to an active control treatment, aflibercept, to better understand how these treatments affect vision and eye health in this condition. Participants are randomly assigned to receive either one dose of 4D-150 or aflibercept injections at scheduled visits. The 4D-150 is given as a single intravitreal injection on Day 1, while aflibercept is administered during follow-up visits as needed. The study includes a 52-week period to assess visual changes and a longer 104-week period to monitor the need for additional aflibercept injections and other eye health measures. During the study, participants will undergo eye exams including measurements of visual acuity using the ETDRS letter score and evaluations of the central subfield thickness in the retina. Researchers will track the number and timing of aflibercept injections and monitor any anatomical or functional changes in the treated eye. Safety and stability of vision will be observed throughout the trial period, which lasts up to two years.